Our first experiences in applying an original method for removal of ABO-isoagglutinins in ABO-incompatible kidney recipients by Ignjatović Ljiljana et al.
Volumen 66, Broj 2 VOJNOSANITETSKI PREGLED Strana 117
Correspondence to: Ljiljana Ignjatović, Military Medical Academy, Clinic of Nephrology, Department of Kidney Transplantation,
Crnotravska 17, 11 090 Belgrade, Serbia. Phone: + 381 11 367 07 84, + 381 11 3608 128. E-mail: ljiljatx@yahoo.com
O R I G I N A L  A R T I C L E UDC:  616.61-089.843:612.017.1
Our first experiences in applying an original method for removal of
ABO-isoagglutinins in ABO-incompatible kidney recipients
Naša prva iskustva u primeni originalne metode za snižavanje titra ABO
izoaglutinina kod ABO inkompatibilnih transplantacija bubrega
Ljiljana Ignjatović*, Zoran Kovačević*, Dragan Jovanović*, Neven Vavić*,
Zoran Paunić*, Milorad Radojević*, Violeta Rabrenović*,
Katarina Obrenčević*, Mirjana Mijušković*, Biljana Draškovic-Pavlović
†,
Gordana Ostojić
‡, Bela Balint
‡, Dubravko Bokonjić
§
Military Medical Academy, *Clinic of Nephrology, 
†Institute of Medical Research,
‡Institute of Transfusiology, 
§Poison Control Center, Belgrade, Serbia
Abstract
Background/Aim. Due to improved methods for removal
of ABO isoagglutinins and novel immunosuppressive proto-
cols, short and long term outcome in blood group incom-
patible is similar to blood group compatible kidney trans-
plantation. The aim of this study was to determine the effi-
cacy of our original method for removal of ABO isoaggluti-
nins from the blood in ABO-incompatible kidney allograft
recipients. Method. Between 2006 and 2008 twelve patients
were transplanted from ABO incompatible living donors.
Titers of ABO isoagglutinins were 4–128 (IgG). Immuno-
suppressive therapy started 14 days before kidney transplan-
tation with rituximab, followed by a triple therapy (predni-
sone + tacrolimus + mycophenolate mofetil) and the first
plasma exchange (PE) procedure, in which one plasma vol-
ume was substituted with albumin and saline on day 7 before
transplantation. For selective extracorporeal immunoadsorp-
tion, the removed plasma was mixed with donor blood type
filtered red blood cells, centrifuged and the supernatant sepa-
rated and preserved. In the next PE procedure, the removed
plasma was replaced with immunoadsorbed plasma, and so
on. Titers of ABO agglutinins, renal allograft function and
survival were followed-up. Results. The pre-transplant
treatment consisting of 1–5 PE procedures and immunosup-
pressive therapy resulted in target ABO agglutinins titers be-
low 4. During a 10–24 month follow-up three patients had an
early acute rejection, one patient acute rejection and hemo-
lytic anemia, two patients surgical complications and one of
them lost his graft. In the post-transplant period, the titers of
ABO antibodies remained below 4. All the patients had stable
kidney allograft function with mean serum creatinine ±SD of
129 ± 45 μmol/l at the end of the study. Conclusion. Our
method for removal of ABO antibodies was effective in a
limited series of patients and short-term follow-up.
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Apstrakt
Uvod/Cilj. Zahvaljujući poboljšanju metoda za snižavanje titra
ABO izoaglutinina i novim imunosupresivnim protokolima,
kratkoročno i dugoročno preživljavanje transplantiranih bubrega
je slično kod bolesnika kojima je transplantacija urađena preko
krvno grupne barijere u odnosu na krvno grupno podudarne.
Cilj ovog ispitivanja bio je određivanje efikasnosti naše original-
ne metode u smanjivanju titra ABO izoaglutinina u krvi bolesni-
ka kojima je bubreg transplantiran preko krvno grupne barijere.
Metod. Od 2006. do 2008. urađeno je dvanaest transplantacija
bubrega od krvno grupno nepodudarnih živih davalaca. Titar
ABO izoaglutinina bio je 4–128 (IgG). Sa imunosupresivnom
terapijom počinjalo se 14 dana pre transplantacije rituksimabom,
a nastavljalo se sedam dana pre transplantacije trojnom terapi-
jom (prednizon+takrolimus+mikofenolat mofetil) i plazmefere-
zom u kojoj je izdvojena plazma supstituisana albuminima i fizi-
ološkim rastvorom. Tokom selektivne ekstrakorporalne imuno-
adsorpcije (SEKIA) izdvojena plazma mešana je sa eritrocitima
davaočeve krvne grupe, centrifugovana, a supernatant je odva-
jan i konzerviran. Tokom sledeće plazmafereze, izdvojena pla-
zma supstituisana je imunoadsorbovanom plazmom. Broj pro-
cedura određivan je postizanjem ciljnog titra izoaglutinina < 4
(IgG). Tokom praćenja registrovani su titar izoaglutinina, funk-
cija i preživljavanje grafta. Rezultati.  U pretransplantacionoj
pripremi urađeno je 1–5 plazma izmena i sa imunosupresivnom
terapijom postignut je titar izoaglutinina < 4. Tokom praćenja
od 10 do 24 meseca tri bolesnika su imala epizodu ranog akut-
nog odbacivanja, jedan akutno odbacivanje i hemolitičku ane-
miju, dva hirurške komplikacije, od kojih je jedan izgubio graft.
U posttransplantacionom periodu titrovi izoaglutinina ostali su
< 4. Na kraju praćenja svi bolesnici imali su stabilnu funkciju
alografta sa serumskim kreatininom 129 ± 45 μmol/l. Zaklju-
čak. Na malom broju bolesnika sa bubregom transplantiranim
preko krvno grupne barijere i uz nedovoljno dugo praćenje naš
protokol za smanjenje titra ABO antitela pokazao se efikasnim.
Ključne reči:
transplantacija bubrega; abo sistem; krvne grupe,
nepodudaranje; plazmafereza; antitela; graft,
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Introduction
In the past, preparations for kidney transplantation
across blood groups were demanding, and often included
extensive surgery 
1. Over the last 10 years, methods for re-
moval of ABO isoagglutinins (plasma exchange, immunoab-
sorption) have improved considerably, and new advances in
immunosuppressive therapy have been made 
2–6. Contrary to
early studies with poor results for kidneys transplantated
across blood groups, recent reports showed short and long
term outcome in kidney transplantation across blood groups
to be similar to those with the same blood type 
7, 8.
Due to legislation and organizational problems at the
national level concerning kidney transplant programs from
deceased donors, only a limited number (about 7%) of kid-
neys are transplanted from cadavers in our institution. In or-
der to increase the number of transplanted patients, we
started with preemptive kidney transplantations from unre-
lated, but emotionally related donors and from incompatible
living donors (with positive cross match and across the blood
group barrier). We developed an original method for removal
of ABO isoagglutinins from the recipient’s blood, which in-
cludes two procedures: plasma exchange (PE) and selective
extracorporeal immunoadsorption (SECIA) of removed
plasma with filtered donor blood group erythrocytes, as “a
closed circuit” 
9. The immunosuppressive protocol  was
adapted from a Swedish preposition for pre- and post-
transplant management in kidney transplantation across
blood groups 
10, 11. The aim of the present study was to in-
vestigate the efficacy of our therapy protocol in a kidney
transplant program across blood groups.
Methods
In the period from April 1, 2006 to April 30, 2008
twelve ABO-incompatible transplantations, in 6 males and 6
females (mean age 40.17 ± 7.64 years) were performed at the
Military Medical Academy, Belgrade. The etiology of end-
stage renal disease was diabetic nephropathy in one patient
and unknown in eleven patients. Donors were living, 11 re-
lated, one unrelated (emotionally related spouse) (mean age
61.92 ± 6.27 years), and with at least 50% Human Leukocyte
Antigens (HLA) matching. Baseline titers of recipients’
ABO isoagglutinins were 4 to 128 (IgG). The age and blood
type of donors and recipients, HLA matching and cross
match are shown in Table 1. Seven recipients with blood
type O had a B type donor, three O type recipients had an A
type donor, one A type recipient had a B type donor and one
B type recipient had an A type donor. The lymphocytotoxic
pre-transplant cross match was negative in all patients, al-
though one patient had a historically positive cross match,
successfully treated with PE, double immunosuppressive
therapy (mycophenolate mofetil and tacrolimus) and rituxi-
mab.
The study was approved by the Ethical Committee of
the Medical Military Academy and a written informed con-
sent was obtained from each donor and recipient.
The day of transplantation was designated as day 0.
Pre-transplant preparation started on day – 14 with rituximab
(375 mg/m
2), followed from day – 7 with triple immunosup-
pressive therapy: prednisone [0.5 mg/kg body weight (BW)],
mycophenolate mofetil in the standard dose of 500 mg bid,
and tacrolimus adjusted to a target C0 concentration of 15–
20 ng/ml. Plasma exchange and SECIA were also performed
on day -7. The first four patients received anti-CD 25 anti-
bodies (daclizumab) twice, as induction therapy on day -1 (2
mg/kg BW) and on day +13 (1 mg/kg BW).
The first  large volume PE  was performed on day -7
with removal of 3.8 ± 0.5 l of plasma and replacement with
20% human albumin in saline. Plasma was exchanged on a
BCT-Spectra instrument (Gambro, Sweden). The removed
plasma underwent SECIA with filtered erythrocytes of the
donor blood type, using the original method of Balint et al. 
9
as described in detail elsewhere. After immunoadsorption,
the supernatant was centrifuged, separated and preserved. In
the second PE procedure, the immunoadsorbed plasma was
used as the replacement fluid. The removed plasma in the
second procedure underwent SECIA, and so on. The number
of PE and SECIA procedures depended on the titer of ABO
isoagglutinins, with the target titer less than 4 (IgG).
The immunosuppressive protocol in the post-transplant
period consisted of prednisone (tapered by standard proto-
Table 1
Basic patients data
Patient
(n)
Donors' age
(years)
Recipients' age
(years)
Donors'
blood type
Recipients'
blood type
HLA*
matching Cross match
15 8 3 6 B + O + 2 / 4 −
2 58 34 B+ O+ 2/4 hystoric +
36 4 5 9 B + O + 2 / 9 −
4 64 42 A1+ O+ 2/4 −
55 5 2 9 B + O - 2 / 4 −
66 5 4 4 B + O + 3 / 9 −
7 73 40 B+ A2+ 2/4 −
85 8 4 1 B + O + 2 / 4 −
96 4 3 6 B + O + 2 / 4 −
10 50 34 A2+ B+ 2/4 −
11 67 46 A1- O+ 2/4 −
12 67 41 A1+ O+ 2/4 −
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col), tacrolimus (dose adjusted to C0 blood concentration)
and mycophenolate mofetil in a standard daily dose of 2 g
for the first 1-3 months and then 1 g daily divided into two
doses. In the follow up period the titers of ABO isoaggluti-
nins (IgG), allograft function (through serum creatinine) and
survival, episodes of rejections and infections were moni-
tored.
Titers of ABO isoagglutinins were measured using a
standard procedure described in detail in the Technical
Manual of the American Association of Blood Banks,
(Mark E Brecher, 15th ed., 1999). Blood groups and Rh
factor were tested with blood grouping reagents ABO-Rh /
Reverse grouping cassette (Ortho-Clinical Diagnostics,
USA). The concentration of tacrolimus before the morning
dose was measured with the Abbot IMx Tacrolimus II As-
say, based on Micro particle Enzyme Immunoassay
(MEIA). Serum creatinine concentrations were determined
colorimetrically by the Bonsnes and Taussky method on a
Dade Behring instrument.
According to transplantation protocol of our institution
diagnosis of early acute rejection (in the first 15 postrans-
plant days) was based on clinical presentation, laboratory
findings and response to steroid pulse therapy. In the cases
resistant to steroid therapy kidney allograft biopsy was per-
formed. The cut-off level for diagnosis of reactivated cyto-
megalovirus (CMV) was 400 copies/ml [Polymerase Chain
Reaction (PCR) Amplicor, Hoffman La Roche]. Bacterial in-
fections were diagnosed according to positive cultures, he-
matological and biochemical parameters and clinical pres-
entation.
The efficacy of the PE + SECIA procedure is shown as
individual IgG isoagglutinin titers before and after the proce-
dure, and as a mean percentage of the antibody reduction per
procedure. The reduction of ABO isoagglutinins titers per
procedure was analyzed with the Wilcoxon matched pairs
test using a standard statistical program (Stat for Windows,
R.4.5, Stat Inc, SAD 1993). Differences were considered
statistically significant at p < 0.05.
Results
The main criteria for the number of PE procedures with
immunoadsorbed plasma in the pre-transplant period was the
titer of ABO isoagglutinins (IgG). Most of our patients had
1–3 procedures. Three patients  with hemolytic ABO anti-
bodies had 5 pre-transplant modified PE procedures. For
these patients in first two PE procedures, instead of immuno-
adsorbed auto-plasma, immunoadsorbed allo-plasma or AB
blood type plasma was used. None of the patients exhibited
side effects after rituximab, PE with immunoadsorbed
plasma and the triple immunosuppressive protocol. The first
PE+SECIA procedure was very effective in reducing anti-
donor BG antibodies (antibodies to white cell antigen rem-
nants on red cells), but all patients showed the rebound phe-
nomenon after the first procedure. After 3–5 procedures
there were no rebounds, and the titers of ABO isoagglutinins
(IgG) were within the reference range (below 4). The per-
centage reduction of ABO isoagglutinins (IgG) for PE with
immunoadsorbed plasma was: 65.9 ± 12.61% after the first,
47.72 ± 26.11 after the second, 60 ± 12.8 after the third, 75%
after the fourth, 81.25 ± 8.83% after the fifth and 50% after
the sixth procedure (Table 2).
Selective extracorporeal immunoadsorption was very
efficient in reducing ABO isoagglutinins: 91.4 ± 17.3% after
the first, 88.75 ± 17.13% after the second, 88.75 ± 17.13%
after the third, 78.13 ± 21.35 after the fourth, and 100% after
the fifth, procedure (Table 3).
In the post-transplant period 1–3 preemptive PE proce-
dures with immunoabsorbed plasma were performed in spite
of the very low isoagglutinin titers only in the first three pa-
tients. Neither of these procedures was performed in the re-
maining eight patients. In all the patients the titer stayed very
low during the whole follow up period, so we did not have to
administer additional immunosuppressive therapy or PE with
immunoadsorbed plasma procedures. The titers of ABO iso-
agglutinins in the post-transplant months are presented in
Table 4.
Table 2
The titers of ABO isoagglutinins (IgG) at the start and in the end of the plasma exchange (PE)
with human albumines (PE 0) and immunoadsorbed plasma (PE 1–5)
PE 0 PE 1 PE 2 PE 3 PE 4 PE 5 Patient (n) start end start end start end start end start end start end
1 32 8 16 4 8 4 8 2
21 6 8 8 4 8 2
3 128 32 32 8 16 8 32 8 16 4 2 1
4 64 32 32 16 16 8 16 4
54 2 4 2
6 32 8 16 16 16 4
73 2 8 2 1 2 1
88 2 4 2 4 2
9 1 6 4 84 1 6 88481
10 32 8 8 2 8 2 32 4 8 4
11 32 16 4 4 8 2
12 64 16 16 8 8 4
% of reduction
± SD
-65.91
± 12.61
-47.72
± 26.11
-60.0
± 12.9
-75.0
± 0.0
-81.25
± 8.8
-50.0 ± 0
± 0.0
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The first four patients received anti-CD25 antibodies
and two of them experienced clinical and laboratory signs of
acute steroid sensitive rejection. At the time of acute rejec-
tion tacrolimus C0 was somewhat below 15 ng/ml in both
patients. Anti-CD25 antibodies were not used in the next
eight patients. Their C0 concentration of tacrolimus before
transplantation reached the target value of 15–20 ng/ml. Two
of these eight patients had early episodes of acute rejection,
and both were successfully treated with 5 × 500 mg methyl-
prednisolone pulses. One to three months after the trans-
plantation, the dose of mycophenolate mofetil was decreased
by 50%, without further rejection episodes.
Two of our patients had serious surgical complica-
tions. The first had life threatening bleeding in the abdomi-
nal wall requiring massive transfusions of filtered red blood
cells and donor-type fresh frozen plasma. He also had uri-
noma and repeated episodes of acute pyelonephritis, which
resolved with successful surgical treatment. The second
patient had repeated surgical treatments for bleeding from
the operative field complicated with recurrent sepsis with
resistant  Pseudomonas aeruginosa and the syndrome of
multi-organ dysfunction (MODS). He lost kidney graft
function within 6 days. These two patients had no abnor-
malities in coagulation or increased titers of alloantibodies
or isoagglutinins.
All the patients had at least one symptomatic or
asymptomatic urinary tract infection during the follow up.
Four patients with reactivated cytomegalovirus infection
were successfully treated with intravenous gancyclovir. One
patient had primary cytomegalovirus infection, and received
intravenous gancyclovir for 28 days, and then oral acyclovir
400 mg daily for 6 months.
With the exception of the single patient (sepsis and
MODS), who lost kidney function early after transplantation,
all the remaining patients had stable renal function (esti-
mated by serum creatinine) during the follow up. Mean cre-
atinine level in these patients was 129 ± 45 μmol/l. Only one
patient (with urinoma and multiple surgical treatments) had a
creatinine concentration slightly above 200 μmol/l, which
remained stable during the follow up. Individual serum cre-
atinine levels in the examined patients throughout the post-
transplant period are presented in Figure 1.
Table 3
The titers of ABO isoagglutinins (IgG) at the beginning and in the end of
selective extaacorporeal immunoadsorption (SECIA)
1. SECIA 2. SECIA 3. SECIA 4. SECIA 5. SECIA Patient
start end start end start end start end start end
1 1 6 1804 0 4 0 1 0
2 80404 0 1 0
3 6 4 H * 1 641 6 4 81
43 2 H * 8 H * 1 6 2 1 6 4
5 21211 0
6 8 11 60 8 0
7 40202 0
8 40202 0
9 84428 2 8 0
10 16 H* 4 1 4 1 4 2
1 1 80804 0
12 16 0 8 1 2 1
% of reduction
±SD
-91.4
± 17.33
-88.75
± 17.13
-88.75
± 17.12
-78.125
± 21.34
-100
± 0
p 0.003 0.005 0.005 0.067
*H – value than normal ones higer
Table 4
ABO isoagglutinin titers (IgG) in months after transplantation
Post- transplant months
Patient 1234567891 01 11 21 41 61 82 02 22 4
1 1 1 1 1 1 1 1 0 0 000000000
2 1 1 1 1 1 1 1 1 1 11000000
3 2 1 1 1 1 1 2 1 2 11101000
4 2 4 4 4 4 2 2 1 1 00000
5 1 1 0 0 0 0 0 0 0 00000
6 1 1 1 1 1 1 1 1 1 00000
7 0 0 0 0 0 0 0 0 0 00000
8 0 0 0 0 1 0 1 0 1 11111
1 0 4 4 4 4 1 1 2 2 4 4421
1 1 101011210 0 0
1 2 200210010 0Volumen 66, Broj 2 VOJNOSANITETSKI PREGLED Strana 121
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Fig. 1 – Serum creatinine in post-transplant period
Discussion
Unlike the majority of transplant professionals who use
PE for removal of anti-donor BG antibodies in the pre- and
post-transplant period, Tyden et al. 
10, 11 proposed selective,
antigen-specific immunoadsorption as a safe and effective
procedure. This method had several advantages over the
standard PE procedures including minimal loss of coagula-
tion factors, proteins and electrolytes and to be relatively
ease of application. The remaining problem is a prediction of
the right number of columns for immunoadsorption per pa-
tient, because the number of columns depends on the
achieved isoagglutinins titer. The number reported varied
from 7 to 26 columns per patient. In addition, considerable
time is necessary to acquire the columns, which may not be
acceptable in emergency situations. Our centre proposed a
combination of PE and consecutive SECIA of ABO isoag-
glutinins with filtered erythrocytes of the donor blood type.
The proposed procedure was tested and shown to be safe and
effective in preserving plasma composition and reducing iso-
agglutinin titers 
9. After a pilot study, it was used in twelve
kidney transplant recipients who  were the subject of this
study. The great advantage of this procedure compared to
antigen specific immunoadsorption is the low price, com-
bined with good safety and efficacy. Patients who had ABO
agglutinin antibodies needed 2–3 procedures prior to trans-
plantation, while those with hemolytic antibodies required 3–
5 procedures pre-transplant. In the post-transplant period,
extra procedures were not necessary, but, due to lack of ex-
perience, this was done pre-emptively in the first three pa-
tients. As part of the pre-transplant preparation, all our pa-
tients were given only one dose of rituximab adjusted to the
body surface area, and none of them needed it in the post-
transplant period. In the postoperative period the patients re-
ceived only a maintenance immunosuppressive protocol,
with the exception of four patients with signs of acute rejec-
tion who were treated with methylprednisolone pulses.
The kidney donors had blood types A1, A2, and B and
the recipients O, A2 and B. Tyden et al. 
10, 11 also proposed
an immunosuppressive protocol without splenectomy for the
same blood group combinations and reported encouraging
results in graft function, an acceptable number of acute re-
jection episodes and antibody mediated rejections with good
response to standard therapy. In comparison to the immuno-
suppressive protocol proposed by Tyden’s group, in our
protocol intravenous immunoglobulin was excluded and, af-
ter the first four transplantations, induction therapy with
monoclonal anti-CD 25 antibodies was also excluded. The
use of intravenous immunoglobulin was proposed in order to
scavenge HLA alloantibodies and minimize the chance of
antibody-mediated rejection. However, as intravenous im-
munoglobulin contains small amounts of alloantibodies, they
can promote an antibody-mediated rejection (own unpub-
lished data). In the follow-up period we noticed acceptable
rates of acute steroid-sensitive rejections (30%). Other
authors also found similar rates of acute rejections 
10, 11.
Considering that most kidney donors were marginal
with a mean age of 61.92 ± 6.27 years, renal allograft func-
tion was satisfactory, with mean serum creatinine of
129 ± 45 μmol/L, which remained stable during the follow-
up. Allograft function and complications after kidney trans-
plantation across blood groups appeared with similar fre-
quency and clinical features as in the ABO compatible kid-
ney transplantations performed in our institution 
12, 13.
Limitations of the study: This is a case-series study
presenting preliminary experience in a single centre with a
specific, modified protocol applied in the care of these
complex patients. The study does not compare the results
with those for patients with matching ABO donors or with
different treatment protocols. However, our results are en-
couraging and warrant further prospective trials that would
address these issues. The diagnosis of acute rejection was
made according to clinical and laboratory findings and the
response to steroid pulse therapy but was not confirmed by
kidney biopsy. Although this is a limitation of the study,
the post-transplant course and response to steroid pulse
therapy in the patients with the clinical presentation of
acute rejection indicated that acute rejection was not a sig-
nificant problem in the presented incompatible living kid-
ney donor transplantations.
Conclusion
Our original method for removal of anti-donor BG abs in
patients receiving kidney transplant from ABO-incompatible
donors appears to be safe and effective. The overall survival,
complication rates and post-transplant kidney function are com-
parable to the historical data from ABO-compatible patients.
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